


## TT-103MH

will be submitted to the U.S. Food and Drug Administration (FDA) with the aim to obtain the Orphan Drug Designation for topical treatment in patients with von Willebrand factor deficiency.

Effects of topical administration of TT 103MH (400 ng/ml) in a several hemorrhage model in von Willebrand Factor deficient mice.



To test pro-coagulant effect of TT-103 MH when administered topically, four groups (5 animals per group) of haemophilic mice obtained by gene-targeted mutation (von Willebrand Factor deficiency) were formed; two of male and two female specimen. They were subjected to tail vein resection. Immediately after that each group of mice was topically treated at the site of resection with either TT-buffer or TT-103 MH. Furthermore a control group of 5 healthy animals was included. These animals were subjected to vein resection and thereafter treated with TT-buffer as well. Then duration of the hemorrhage and the rate of mortality in each group were determined.